Journal
NATURE MEDICINE
Volume 23, Issue 4, Pages 508-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.4295
Keywords
-
Funding
- JSPS KAKENHI [25461334, 25292078, 16K09740, 26461329, 26253046]
- Mochida Memorial Foundation for Medical and Pharmaceutical Research
- Takeda Science Foundation
- MEXT-Supported Program for the Strategic Research Foundation at Private Universities in Japan
- JST Adaptable and Seamless Technology Transfer Program (A-STEP) [AS2311400F, 15im0302407]
- Grants-in-Aid for Scientific Research [17H04199, 26461329, 25461334, 15H04809, 16K09740, 26253046, 26461328] Funding Source: KAKEN
Ask authors/readers for more resources
Exercise has numerous health-promoting effects in humans(1); however, individual responsiveness to exercise with regard to endurance or metabolic health differs markedly(2-4). This 'exercise resistance' is considered to be congenital, with no evident acquired causative factors. Here we show that the anti-oxidative hepatokine selenoprotein P (SeP)(5-7) causes exercise resistance through its muscle receptor low-density lipoprotein receptor-related protein 1 (LRP1)(8). SeP-deficient mice showed a 'super-endurance' phenotype after exercise training, as well as enhanced reactive oxygen species (ROS) production, AMP-activated protein kinase (AMPK) phosphorylation(9) and peroxisome proliferative activated receptor gamma coactivator (Ppargc)-1 alpha (also known as PGC-1 alpha; encoded by Ppargc1a)(10) expression in skeletal muscle. Supplementation with the anti-oxidant N-acetylcysteine (NAC) reduced ROS production and the endurance capacity in SeP-deficient mice. SeP treatment impaired hydrogen-peroxide-induced adaptations through LRP1 in cultured myotubes and suppressed exercise-induced AMPK phosphorylation and Ppargc1a gene expression in mouse skeletal muscle-effects which were blunted in mice with a muscle-specific LRP1 deficiency. Furthermore, we found that increased amounts of circulating SeP predicted the ineffectiveness of training on endurance capacity in humans. Our study suggests that inhibitors of the SeP-LRP1 axis may function as exercise-enhancing drugs to treat diseases associated with a sedentary lifestyle.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available